Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

Inclusion Criteria: * Patients must have pathologically confirmed, previously untreated, resectable, squamous cell carcinoma of the larynx. * Disease must be Stage III or IV. * Tumor must be potentially surgically resectable and curable with conventional surgery and radiation therapy. * Patients must undergo pre-treatment endoscopic tumor staging and CT scanning. * ECOG Performance status 0-2 * Pre-treatment laboratory criteria: * WBC \> or = to 3500/ul, granulocyte \> or = to 1500/ul. * Platelet count \> or equal to 100,000/ul. * Calculated or measured creatinine clearance \> or = to 60 cc/min. * Total Bilirubin \< or = to 1.5 X ULN. * AST and ALT \< or = to 2.5 X ULN. * Patients must give documented informed consent to participate in this study. Exclusion Criteria: * Prior head and neck malignancy or history of other prior non-head and neck malignancy within the past 3 years. * Prior head and neck radiation or prior chemotherapy. * Documented evidence of distant metastases. * Active infection. * Pregnancy or lactation. Patients must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy. * Any medical or psychiatric illness which in the opinion of the principal investigator would compromise the patients ability to tolerate this treatment. * Patients residing in prison. * Age \< 18 years. * Patients with psychiatric/social situations that would limit compliance with study requirements are not eligible. * Patients with prior radiation to the head and neck. * Patients with prior anti-epidermal growth-factor receptor antibody therapy or therapy with a tyrosine-kinase inhibitor. * Patients with Grade \> 2 peripheral neuropathy. * Any history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80.